A retrospective evaluation of the effects of deuterium depleted water consumption on 4 patients with brain metastases from lung cancer.
OBJECTIVE
Because of the number of sufferers and high mortality rate, the standard care and new therapeutic options in the treatment of brain metastasis from lung cancer are the subject of intense research. A new concept based on the different chemical and physical behavior of protium and deuterium affecting cell signaling and tumor growth has been introduced in the treatment of cancer patients. The aim of this study was to investigate the impact of deuterium depleted water (DDW) consumption in addition to conventional forms of therapy on the survival of lung cancer patients with brain metastasis.


METHODS
A series of 4 case histories was retrospectively evaluated. The patients were diagnosed with brain metastasis deriving from a primary lung tumor and started consuming DDW at the time of or after the diagnosis of the brain metastasis, which was inoperable or the surgical intervention did not result in complete regression. The primary objective was survival.


METHODS
The daily water intake of the patients was replaced with DDW, which complemented the conventional forms of treatment. Patients were consuming DDW for at least 3 months. The treatment was continued with DDW of 10 to 15 to 20 ppm lower deuterium (D) content every 1 to 2 months and thus a gradual decrease was maintained in the D-concentration in the patient's body.


RESULTS
DDW consumption integrated into conventional treatments resulted in a survival time of 26.6, 54.6, 21.9, and 33.4 months in the 4 patients, respectively. The brain metastasis of 2 patients showed complete response (CR), whereas partial response (PR) was detected in 1 patient, and the tumor growth was halted (no change or NC) in 1 case. The primary tumor of 2 patients indicated CR, and the lung tumor in 2 patients showed PR.


CONCLUSIONS
DDW was administered as an oral anticancer agent in addition to conventional therapy, and noticeably prolonged the survival time of all 4 lung cancer patients with brain metastasis. We suggest that DDW treatment, when integrated into other forms of cancer treatment, might provide a new therapeutic option.
Krempels
Krisztina
K
HYD LLC for Cancer Research and Drug Development, Budapest, Hungary.
Somlyai
Ildikó
I
Somlyai
Gábor
G
D000328:Adult; D001932:Brain Neoplasms / Q000503:physiopathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D003903:Deuterium / Q000737:chemistry* / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015398:Signal Transduction; D015996:Survival Rate; D016896:Treatment Outcome; D014867:Water / Q000737:chemistry / Q000494:pharmacology*
D014867:Water; D003903:Deuterium